NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

NWBO has been made aware of deepcapture Dendreon story based on my sending to Les Goldman over 2.5 years ago that particular link. AND it was included in this FIRST post of mine on NWBO:

The investment process as it relates to biotecs is exceedingly complex as it stands, and complicated by the readings of deepcapture.com, compounded by inaccuracies/taking statements out of context/death by a thousand cuts by bloggers as AF with deep affiliations who appear exceedingly desperate lately to enact such major NWBO market manipulations IMHO. To withstand these tidal waves (in the clear absence of NWBO press releases) one needs to be thoroughly versed and up to date in SEC filings, rather than add more UNNEEDED fuel for currently desperate shorts or the motivations of Dr. Buzman and MD Anderson. And the most comprehensive single source IMHO is Nasdaq.com as it relates to 10K(aka annual Bible); 10Q; Def14(Proxy); Short Interest (think it's 7 days after 15th/30th of each month); Institutional Ownership (mininum 6 wks lag from closing qtr); AH trading etc.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=103831978

Moreover, CEO Linda Powers did do a masterful strategic analysis in 2010 BEFORE becoming CEO on the pitfalls of DNDN's product conceptualization issues that were the key to it's demise along with BAD management. which was contained in the WHY NWBO HAS SUPERIOR TECHNOLOGY as well as a fraction of the cost vs that of clearly dethroned and nearing extinction (DNDN's Provenge): contained in the July 15, 2010 CEO Linda Powers Interview by M.E. Garza:

Cancer Vaccines: Northwest Biotherapeutics -vs- Dendreon

By M.E.Garza
Thursday, 15 July 2010 04:59

which I included in:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104962848

Do read entirety of Post # 66538:
In biotech, the tipping point into bankruptcy isn’t often debt butproduct failure, says Robert Eisenbach, bankruptcy counsel at the law firm Cooley.

Provenge was the most complicated and expensive-to-manufacture of all cancer vaccines developed. Yet it drew investors, while simple vaccines that might protect many patients against recurrence, or might protect us from getting cancer at all, get overlooked.

Best single read on DNDN:
http://www.xconomy.com/national/2011/08/08/dendreon-wounds-are-self-inflicted-not-the-start-of-a-biotech-industry-virus/?single_page=true

DIFFERENT STROKES FOR DIFFERENT FOLKS